Tag: CBSO

Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework

The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach BAAR, Switzerland, July 1, 2020 /PRNewswire/ — CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration […]

Carag First-ever Septal Occluder With Bioresorbable, Metal-free Framework Available to Patients Through New European Registry

First 3-year-old patient successfully implanted and discharged from hospital in Berlin BAAR, Switzerland and BERLIN, March 10, 2020 /PRNewswire/ — CARAG AG, a Swiss privately held medical device development company, announced today the successful implantation of the first-ever transcatheter septal occluder with bioresorbable, metal-free […]